These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 15742604)

  • 1. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
    Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
    Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Histological and molecular classification of gliomas].
    Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
    Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnostics of gliomas: the clinical perspective.
    Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
    Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update on the molecular biology of gliomas: towards a pathomolecular classification of gliomas].
    Idoate MA; Echeveste J
    Rev Neurol; 2007 Feb 16-28; 44(4):217-24. PubMed ID: 17311212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
    Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic markers as predictors of response to chemotherapy in gliomas.
    Idbaih A; Omuro A; Ducray F; Hoang-Xuan K
    Curr Opin Oncol; 2007 Nov; 19(6):606-11. PubMed ID: 17906460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity.
    Walker C; du Plessis DG; Joyce KA; Machell Y; Thomson-Hehir J; Al Haddad SA; Broome JC; Warnke PC
    Clin Cancer Res; 2003 Oct; 9(13):4841-51. PubMed ID: 14581356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
    Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
    Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond grade: molecular pathology of malignant gliomas.
    Sulman EP; Guerrero M; Aldape K
    Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological classification of brain tumors.
    Pollo B
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profile as a prognostic factor in high-grade gliomas.
    Czernicki T; Zegarska J; Paczek L; Cukrowska B; Grajkowska W; Zajaczkowska A; Brudzewski K; Ulaczyk J; Marchel A
    Int J Oncol; 2007 Jan; 30(1):55-64. PubMed ID: 17143512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
    Hargrave D
    Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A; Duran-Peña A; Bonnet C; Ducray F
    Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.
    Mariani L; Deiana G; Vassella E; Fathi AR; Murtin C; Arnold M; Vajtai I; Weis J; Siegenthaler P; Schobesberger M; Reinert MM
    J Clin Oncol; 2006 Oct; 24(29):4758-63. PubMed ID: 16966689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Towards a molecular classification of gliomas].
    Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
    Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
    Born PW; Broholm H; Laursen H
    Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognostic assessment of 185 newly diagnosed gliomas: Grade III glioma showed prognosis comparable to that of Grade II glioma.
    Shinohara C; Muragaki Y; Maruyama T; Shimizu S; Tanaka M; Kubota Y; Oikawa M; Nakamura R; Iseki H; Kubo O; Takakura K; Hori T
    Jpn J Clin Oncol; 2008 Nov; 38(11):730-3. PubMed ID: 18820008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
    Kim SH; Kim H; Kim TS
    Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-grade gliomas -- current concepts.
    Schramm J; Blümcke I; Ostertag CB; Schlegel U; Simon M; Lutterbach J
    Zentralbl Neurochir; 2006 May; 67(2):55-66. PubMed ID: 16673237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.